May 28th, 2018

Pharmacologic Deficiency in the Women's Health Initiative Study
Authors:  Frank Z. Stanczyk, Ph.D., Sukanya Chaikittisilpa, M.D., and Subir Roy, M.D.
  To the Editors: The Writing Group for the Women's Health Initiative (WHI) investigation reported that overall health risks exceeded benefits from use of a combined estrogen-progestin formulation (PremproTM, Wyeth Pharmaceuticals, Collegeville, Pennsylvania), containing 0.625 mg conjugated equine estrogens (CEE) and 2.5 mg medroxyprogesterone acetate (MPA), after an average 5.2-year follow-up among healthy, postmenopausal women.1 The investigators concluded that this formulation is not consistent with the requirements for primary prevention of chronic diseases, including coronary heart disease (CHD).
The mean (SD) age of the women was 63.3 (7.1) years. Approximately one-third of them were 50-59 years old, almost one-half (45.3%) were aged 60-69 years, and approximately one-fifth were 70-79 years old. Thus, a significant number of these women were >65 years of age. This group can be considered elderly postmenopausal women.
Keywords:  hormone replacement therapy, cardiovascular disease, Women's Health Initiative
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from